Latest from USC Norris

Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, discusses the role of ramucirumab in advanced hepatocellular carcinoma.
Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses next steps with immunotherapy in metastatic colorectal cancer.
Anthony B. El-Khoueiry, MD, provides insight on the rapidly evolving treatment options in hepatocellular carcinoma.
Heinz-Josef Lenz, MD, associate director for Adult Oncology and co-leader of the Gastrointestinal Cancers Program, USC Norris Comprehensive Cancer Center, discusses frontline nivolumab plus ipilimumab in metastatic colorectal cancer.
Anthony B. El-Khoueiry, MD, associate professor of clinical medicine, Keck School of Medicine, USC Norris Comprehensive Cancer Center, distinguishes between lenvatinib and sorafenib for the frontline treatment of advanced hepatocellular carcinoma.
Bing Xia, MD, discusses the latest immunotherapy developments in nonsquamous non–small cell lung cancer, as well as sequencing strategies for patients with ALK-positive disease.
USC Norris Comprehensive Cancer Center has launched a study to determine how financial assistance for costs associated with clinical trial participation might increase enrollment, particularly among low-income patients and racial and ethnic minorities.
David I. Quinn, MD, PhD, associate professor of medicine, section head, Genitourinary Oncology, Division of Cancer Medicine and Blood Diseases, Keck School of Medicine, discusses the current state of biomarkers in renal cell carcinoma.
Publication Bottom Border
Border Publication
x